Aduro Biotech to Present at JP Morgan Healthcare Conference

BERKELEY, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, was invited to present at the 34th Annual JP Morgan Healthcare Conference in San Francisco, CA on Thursday, January 14, 2016, at 10:30 am Pacific Time.

To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.

About Aduro

Aduro Biotech, Inc. is a clinical-stage immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.

Contact:   
Sylvia Wheeler  
SVP, Corporate Affairs 
510 809 9264 
  
Media Contact:
Angela Bitting
925 202 6211

Mike Beyer
Sam Brown, Inc.
312 961 2502
[email protected]

You May Also Be Interested In

• Gold Coast Health Plan Celebrates 15 Years of Growth and Impact in Serving Ventura County's Medi-Cal Members
• Siddharth Mittal Appointed as Managing Director & CEO of Syngene International
• Compass Diversified Declares Second Quarter 2026 Distributions on Series A, B and C Preferred Shares